
Join to View Full Profile
1950 Circle of Hope DrSalt Lake City, UT 84112
Phone+1 801-213-3800
Fax+1 801-715-8228
Dr. Sborov is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Education & Training
- Ohio State University HospitalFellowship, Hematology and Medical Oncology, 2012 - 2015
- University of Utah HealthResidency, Internal Medicine, 2009 - 2012
- American University of the Caribbean School of MedicineClass of 2009
Certifications & Licensure
- CO State Medical License 2022 - 2027
- MT State Medical License 2022 - 2026
- UT State Medical License 2010 - 2026
- ID State Medical License 2022 - 2025
- NV State Medical License 2023 - 2025
- WY State Medical License 2022 - 2025
- OH State Medical License 2012 - 2018
- American Board of Internal Medicine Internal Medicine
- American Board of Internal Medicine Hematology
- American Board of Internal Medicine Medical Oncology
Clinical Trials
- Study of Disulfiram and Copper Gluconate in Patients With Treatment-Refractory Multiple Myeloma Start of enrollment: 2021 May 21
Publications & Presentations
PubMed
- Outcomes and treatment patterns in primary and secondary plasma cell leukemia: insights from a large US cohort study.Shagun Singh, Supriya Peshin, Betsy C Wertheim, Ashley Larsen, Iloabueke Chineke
Haematologica. 2025-04-17 - Persistent opioid use is associated with a shorter myeloma survival.Karen Sweiss, Ana Maria Avila Rodriguez, John G Quigley, Lisa Sharp, Kaily Kurzweil
Supportive Care in Cancer. 2025-04-11 - Teclistamab for Patients with Heavily Pretreated Relapsed/Refractory Multiple Myeloma and Renal Impairment.Danai Dima, Aimaz Afrough, Utkarsh Goel, Ariel Grajales-Cruz, Jack Khouri
Blood Advances. 2025-04-08
Abstracts/Posters
- Depth of Response to Daratumumab (DARA), Lenalidomide, Bortezomib, and Dexamethasone (RVd) Improves over Time in Patients (pts) with Transplant-Eligible Newly Diagnose...Douglas W. Sborov, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
- Proteasome Inhibitors Impair the Innate Antiviral Immune Response and Potentiate Pelareorep-Based Viral Therapy in Multiple MyelomaDouglas W. Sborov, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
Press Mentions
- Quad Combination for Myeloma Brings PFS AdvantageAugust 29th, 2022
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence: